title: Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes.
authors.affiliation: Department of Medicine, University of Calgary, Calgary, Alta. doreen.rabi@albertahealthservices.ca
authors.forename: Doreen M
authors.initials: DM
authors.lastname: Rabi
authors.forename: Raj
authors.initials: R
authors.lastname: Padwal
authors.forename: Sheldon W
authors.initials: SW
authors.lastname: Tobe
authors.forename: Richard E
authors.initials: RE
authors.lastname: Gilbert
authors.forename: Lawrence A
authors.initials: LA
authors.lastname: Leiter
authors.forename: Robert R
authors.initials: RR
authors.lastname: Quinn
authors.forename: Nadia
authors.initials: N
authors.lastname: Khan
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents